These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6781082)

  • 1. Economic aspects of the management of ocular hypertension.
    Worthen DM
    Surv Ophthalmol; 1980; 25(3):206-14. PubMed ID: 6781082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "no treatment" approach to ocular hypertension.
    Phelps CD
    Surv Ophthalmol; 1980; 25(3):175-82. PubMed ID: 7008229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial.
    Lamoureux EL; Mcintosh R; Constantinou M; Fenwick EK; Xie J; Casson R; Finkelstein E; Goldberg I; Healey P; Thomas R; Ang GS; Pesudovs K; Crowston J
    Trials; 2015 Sep; 16():406. PubMed ID: 26362541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Health-economic aspects of glaucoma screening].
    Hirneiss C; Niedermaier A; Kernt M; Kampik A; Neubauer AS
    Ophthalmologe; 2010 Feb; 107(2):143-9. PubMed ID: 19572134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.
    Rouland JF; Berdeaux G; Lafuma A
    Drugs Aging; 2005; 22(4):315-21. PubMed ID: 15839720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blindness prevention through control of ocular hypertension: an epidemiological assessment.
    Daubs JG; Crick RP
    Int Ophthalmol; 1980 Dec; 3(1):43-9. PubMed ID: 6783581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glaucoma screening. A cost-effectiveness analysis.
    Gottlieb LK; Schwartz B; Pauker SG
    Surv Ophthalmol; 1983; 28(3):206-26. PubMed ID: 6422576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual function-specific perimetry for indirect comparison of different ganglion cell populations in glaucoma.
    Sample PA; Bosworth CF; Blumenthal EZ; Girkin C; Weinreb RN
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1783-90. PubMed ID: 10845599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
    De Natale R; Draghi E; Dorigo MT
    Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of ocular hypertension].
    Sun YY; Chen WW; Wang NL
    Zhonghua Yan Ke Za Zhi; 2016 Jul; 52(7):542-6. PubMed ID: 27531115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected clinical outcomes of glaucoma screening in African American individuals.
    Ladapo JA; Kymes SM; Ladapo JA; Nwosu VC; Pasquale LR
    Arch Ophthalmol; 2012 Mar; 130(3):365-72. PubMed ID: 22411665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Kymes S
    Am J Ophthalmol; 2006 Aug; 142(2):354; author reply 354-5. PubMed ID: 16876536
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
    Fiscella R; Walt J
    Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is more always better?
    Tuulonen A
    Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing vision loss from glaucoma: putting data from clinical trials into practice.
    Schoenleber DB
    Mo Med; 2005; 102(1):51-4. PubMed ID: 15754618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of low cost glaucoma screening.
    Niessen AG; Langerhorst CT; Geijssen HC; Greve EL
    Doc Ophthalmol; 1997; 93(4):293-315. PubMed ID: 9665288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.
    Orme M; Boler A
    Pharmacoeconomics; 2006; 24(8):743-50. PubMed ID: 16898845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the lifetime economic consequences of glaucoma in France.
    Philippe Nordmann J; Lafuma A; Berdeaux G
    J Med Econ; 2009 Mar; 12(1):9-16. PubMed ID: 19450060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European glaucoma prevention study design and baseline description of the participants.
    Miglior S; Zeyen T; Pfeiffer N; Cunha-Vaz J; Torri V; Adamsons I;
    Ophthalmology; 2002 Sep; 109(9):1612-21. PubMed ID: 12208707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.